Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03735680 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
A Phase 2 study of Breast Cancer and Prostate Cancer, sponsored by OncoNano Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT03735680 is a Phase 2 study of Breast Cancer and Prostate Cancer that has completed, run by OncoNano Medicine. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03735680, a Phase 2 study of Breast Cancer and Prostate Cancer, has completed, sponsored by OncoNano Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine surgery.
Conditions Studied
Interventions
- DRUG ONM-100
Study Locations (3)
Texas
- The University of Texas Southwestern Medical Center - Dallas
- The University of Texas - M.D. Anderson Cancer Center - Houston
Pennsylvania
- The University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-08-09 |
| Est. Completion | 2021-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03735680
The ClinicalTrials.gov registry entry for NCT03735680 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is OncoNano Medicine, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ONM-100 is the first listed.
NCT03735680 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03735680 about?
NCT03735680 is a clinical study titled "A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer". This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine surgery.
What is the current status of trial NCT03735680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-08-09. Estimated completion is 2021-11-18.
What conditions does trial NCT03735680 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer.
What interventions are being tested in trial NCT03735680?
The interventions under investigation include: ONM-100 (DRUG).
Who is sponsoring clinical trial NCT03735680?
This trial is sponsored by OncoNano Medicine, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03735680 being conducted?
This trial has 3 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.